Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A randomized study

Annals of Oncology

Volumn 11, Issue 11, 2000, Pages 1413-1420

  Sobrero, A ^a   Zaniboni, A ^b   Frassineti, G L ^c   Aschele, C ^d   Guglielmi, A ^a   Giuliani, R ^e   Ravaioli, A ^f   Lanfranco, C ^g   Caroti, C ^d   Arnoldi, E ^h   Barni, S ⁱ   Gallo, L ^d   Pessi, M A ^j   Turci, D ^k   Cortesi, E ^e   Grossi, F ^a   Frontini, L ^l   Piazza, E ^m   Bruzzi, P ⁿ   Labianca, R ^j  

^a UNIVERSITY OF UDINE   (Italy)

^b Casa di Cura Poliambulanza   (Italy)

^c MORGAGNI PIERANTONI HOSPITAL   (Italy)

^d GALLIERA HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f OSPEDALE DEGLI INFERMI   (Italy)

^g Ospedale Civile di Asti   (Italy)

^h BOLOGNINI HOSPITAL   (Italy)

ⁱ TREVIGLIO HOSPITAL   (Italy)

^j Radiation Oncology Radiotherapy   (Italy)

^k SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^l Ospedale San Paolo   (Italy)

^m UNIVERSITY OF MILAN   (Italy)

ⁿ UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

5 fluorouracil; Advanced colorectal cancer; Biochemical modulation; Schedule of administration

Indexed keywords

FLUOROURACIL; FOLINIC ACID; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DYSESTHESIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFUSION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033635586     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026527605389     Document Type: Article

References (40)

1. New directions in the treatment of colorectal cancer: A look to the future
2. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
3. Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases
4. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer; A randomized trial
5. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
6. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
7. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer
8. Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer
9. Fluorouracil in colorectal cancer: A tale of two drugs. Implications for biochemical modulation
10. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules
11. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells
12. Schedule-selective biochemical modulation of 5-fluorouracil: A phase II study in advanced colorectal cancer
13. Schedule selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A multicentric phase II study
14. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer
15. Prolonged infusion of fluorouracil with weekly bolus leucovorin: A phase II study in patients with disseminated colorectal cancer
16. Measuring psychological and physical distressin cancer patients: Structure and application of the Rotterdam symptoms checklist
17. Randomized comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma
18. High-dose vs. low-dose 1-leucovorin as a modulator of five-day 5-fluorouracil in advanced colorectal cancer: A GISCAD phase III study
19. Chi-square tests with one degree of freedom: Extensions of the Mantel-Haenszel procedure
20. Non-parametric estimation from incomplete observations
21. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study
22. A phase II study of weekly 24-hour infusion with high-dose 5-fluorouracil with leucovorin in colorectal carcinoma
23. The modulation of fluorouracii with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial
24. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer
25. Phase III randomized study of two fluorouracil combinations with either interferon-α2a or leucovorin for advanced colorectal cancer
26. A phase III study of recombinant interleukin 2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal cancer
27. A prospectively randomized trial comparing 5-FU bolus with low-dose folinic acid (5-FUFOLld) and 5-FU bolus plus continuous infusion with high-dose folinic acid (LV55-FU2) for advanced colorectal cancer
28. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
29. Open, randomized multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
30. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer
31. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
32. 5-Fluorouracil + 6-S-LV (LV) + levamisolo vs. MTX + 5-FU + LEVA: An Italian Intergroup study of adjuvant therapy for resected colon carcinoma
33. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
34. Activity of continuous infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil
35. A randomized trial of leucovorin (LV) and 5-fluorouracil (5-FU) with or without oxaliplatin in advanced colorectal cancer
36. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial
37. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer
38. CPT-11 alternating with 5-fluorouracil-folinic acid: A multicenter phase II study in first-line chemotherapy of metastatic colorectal cancer. Preliminary results
39. High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in metastatic colorectal cancer: A three-day/three-week schedule
40. A prospective randomized trial of protracted venous infusion fluorouracil with or without mitomycin C in advanced colorectal cancer